Researchers engineer a 'smart bomb' to attack childhood leukemia

November 04, 2014

Fatih Uckun, Jianjun Cheng and their colleagues have taken the first steps towards developing a so-called "smart bomb" to attack the most common and deadly form of childhood cancer -- called B-lineage acute lymphoblastic leukemia (ALL).

In a November study in the new peer-reviewed, open-access journal EBioMedicine, they describe how this approach could eventually prove lifesaving for children who have relapsed after initial chemotherapy and face a less than 20 percent chance of long-term survival.

"We knew that we could kill chemotherapy-resistant leukemia cells if we only knew what made them so resistant. Once we determined the mechanism, the next step was obvious -- to rationally design a drug that would take out that specific target," said Uckun, professor of research pediatrics at the Keck School of Medicine of USC and head of translational research in leukemia lymphoma at the Children's Center for Cancer and Blood Diseases of Children's Hospital Los Angeles.

The target of the "smart bomb" is a defective gene that results in the production of an abnormal form of the protein CD22, which causes cancer stem cells to proliferate and resist chemotherapy. This defective gene can thwart standard treatments for recurrent disease -- including "supralethal" chemotherapy, total-body irradiation (TBI) and bone marrow transplantation.

Uckun's team designed synthetic pieces of genetic material, called RNAi, with the capability to shut down this defective gene. Then Uckun joined forces with Cheng, associate professor of materials science and engineering at the University of Illinois at Urbana-Champaign and an affiliate with the NCI Alliance for Nanotechnology in Cancer. Cheng's team engineered a small subunit of protein, called a polypeptide, to function as delivery system to send the RNAi to its target.

The resulting "smart bomb" has a diameter of only 100 nanometers, making it one of the new generation of nanomedicines that can target disease at a molecular level.

"The goal is to translate our recent research discoveries in nanotechnology and biotherapy into effective patient-tailored treatment programs for the most common form of childhood cancer," said Uckun, who is also a principal investigator with the university-wide USC Stem Cell initiative, bringing together more than 100 faculty members from all disciplines.
-end-
Uckun and his team were supported by funding from USC Stem Cell's Regenerative Medicine Initiative (RMI), a university-wide program kick-started by $1.2 million in funding from Carmen A. Puliafito, dean of the Keck School of Medicine of USC. The award facilitates collaborative interactions among the USC-based regenerative medicine community.

Additional funding came from DHHS grants P30CA014089, U01-CA-151837 and R01CA-154471 from the National Cancer Institute and the Director's New Innovator Award 1DP2OD007246-01 from National Institutes of Health. The Nautica Triathalon and its producer Michael Epstein, Couples Against Leukemia Foundation and Saban Research Institute Merit Awards also supported this work.

University of Southern California - Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.